Rhabdoid Tumor Overview

Save information for later
Sign Up

Learn About Rhabdoid Tumor

What is the definition of Rhabdoid Tumor?
Rhabdoid tumor (RT) is an aggressive pediatric soft tissue sarcoma that arises in the kidney, the liver, the peripheral nerves and all miscellaneous soft-parts throughout the body. RT involving the central nervous system (CNS) is called atypical teratoid Rhabdoid tumor. RT usually occurs in infancy or childhood. In most cases, the first symptoms are linked to the compressive effects of a bulky tumor (such as respiratory distress, abdominal mass, peripheral nerve palsy). In about 90% of cases it is caused by a genetic change in the SMARCB1 gene, which is a tumor suppressor gene. In rare cases, it may be caused by a genetic change in the SMARCA4 gene. No standard care exists for RT, although there are many ongoing studies.
What are the alternative names for Rhabdoid Tumor?
  • Rhabdoid tumor
  • Atypical teratoid rhabdoid tumor
  • BRAIN TUMOR, POSTERIOR FOSSA, OF INFANCY, FAMILIAL
  • Malignant rhabdoid tumor
  • RHABDOID TUMOR PREDISPOSITION SYNDROME 1
  • Rhabdoid sarcoma
  • Rhabdoid tumor predisposition syndrome 2
Who are the top Rhabdoid Tumor Local Doctors?
Elite in Rhabdoid Tumor
Dr. Mrinal M. Gounder
Oncology
Elite in Rhabdoid Tumor
Dr. Mrinal M. Gounder
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mrinal Gounder is an Oncologist in New York, New York. Dr. Gounder is rated as an Elite provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Epithelioid Sarcoma, Liposarcoma, and Liver Embolization.

Mark A. Dickson
Distinguished in Rhabdoid Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology
Distinguished in Rhabdoid Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

 
 
 
 
Learn about our expert tiers
Learn More
Richard F. Riedel
Distinguished in Rhabdoid Tumor
Dr. Richard F. Riedel
Oncology
Distinguished in Rhabdoid Tumor
Dr. Richard F. Riedel
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

View All Doctors
What are the latest Rhabdoid Tumor Clinical Trials?
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2

Summary: Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be h...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Who is this study for: Patients with diffuse intrinsic pontine glioma/Diffuse midline glioma and recurrent or refractory pediatric central nervous system tumors
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Biological
Study Drug: B7H3-specific chimeric antigen receptor T cell
Study Phase: Phase 1

Summary: This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center